SYSTEMS AND METHODS FOR TREATING VITILIGO

• US 20190314306A1
• Filed: 04/23/2019
• Published: 10/17/2019
• Est. Priority Date: 07/01/2016
• Status: Active Grant

• Current Assignee: Transdermal Biotechnology, Inc.
• Original Assignee: Transdermal Biotechnology, Inc.
• Inventors: Perricone, Nicholas V.
• Granted Patent: US 10,695,306 B2
• Time in Patent Office: Days
• CPC Class Codes: A61K 31/19 Carboxylic acids, e.g. valproic acid salicylic acid A61K31/60
• CPC Class Codes: A61K 31/661 Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 47/24 containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
• CPC Class Codes: A61K 8/36 Carboxylic acids; Salts or anhydrides thereof
• CPC Class Codes: A61K 8/365 Hydroxycarboxylic acids; Ketocarboxylic acids
• CPC Class Codes: A61K 8/553 Phospholipids, e.g. lecithin
• CPC Class Codes: A61K 9/0014 Skin, i.e. galenical aspects of topical compositions non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00
• CPC Class Codes: A61K 9/06 Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels composition of ointments, creams or gels A61K47/00
• CPC Class Codes: A61K 9/107 Emulsions ; Emulsion preconcentrates; Micelles composition of emulsions A61K47/00
• CPC Class Codes: A61K 9/127 Liposomes
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61Q 19/04 for chemically tanning the skin topical sun or radiation screening or tanning preparations A61Q17/04

Abstract

The present invention generally relates to systems and methods for treating vitiligo. In one set of embodiments, the present invention comprises a composition comprising pyruvic acid and/or a pyruvate salt. The composition may be formulated for application to the skin of a subject, for instance, as a gel, lotion, cream, ointment, soap, or stick. In some cases, the composition may comprise a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present as a liquid crystal, and/or in liposomes, micelles, or other vesicles. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.

Claims

1-118. -118. (canceled)

119. A method, comprising:

applying, to the skin of a subject having vitiligo, a composition comprising an active agent for treating the vitiligo, the active agent comprising pyruvic acid and/or a pyruvate salt,

wherein the pyruvic acid and/or a pyruvate salt is present at less than about 0.2% by weight.

120. The method of claim 119, wherein the composition comprises pyruvic acid.

121. The method of claim 119, wherein the composition comprises a pyruvate salt.

122. The method of claim 119, wherein the composition is in the form of a gel, lotion, cream, ointment, soap, or stick.

123. The method of claim 119, wherein the formulation is substantially transparent.

124. The method of claim 119, wherein the composition comprises a first phase and a second phase.

125. The method of claim 124, wherein the formulation comprises an emulsion of the first phase and a second phase.

126. The method of claim 124, wherein the formulation comprises a liquid crystal structure of the first phase and a second phase.

127. The method of claim 126, wherein at least a portion of the liquid crystal structure is multilamellar.

128. The method of claim 119, wherein the composition further comprises lecithin.

129. The method of claim 128, wherein the lecithin is present at at least about 0.25% by weight of the formulation.

130. The method of claim 128, wherein the lecithin comprises phosphatidylcholine.

131. The method of claim 128, wherein the lecithin comprises polyenylphosphatidylcholine.

132. The method of claim 131, wherein the polyenylphosphatidylcholine is present at no more than 15% by weight of the formulation.

133. The method of claim 119, wherein the formulation further comprises an emulsifier.

134. The method of claim 119, wherein the formulation further comprises a fatty acid ester.

135. The method of claim 119, wherein the formulation further comprises a transdermal penetration enhancer.

136. The method of claim 119, wherein the composition has a viscosity of at least about 20,000 cP.

137. The method of claim 119, wherein the subject is human.